Biotech Values

[Fress]

Hepion is on this short list, among giants. Hint Hint.
Liver Cirrhosis Market Analysis Major Competitor And Strategies Regional Outlook 2021 To 2026
https://erxnews.com/news/336525/liver-cirrhosis-market-analysis-major-competitor-and-strategies-regional-outlook-2021-to-2026/

They can tout Madrigal's P3 lead NASH drug all they want, but the fact of the matter is that it didn't move their stock up, and it actually ended down a bit, very close to the 52-week low.
That sure as hell doesn't sound like any sort of a blockbuster.
The big operators all have top researchers, and you can see they were about as far from jumping through flaming hoops as one could be, when this data was presented at EASL.
Either something ain't quite right with their drug, or there's something the big boys know about that's coming from elsewhere that blows away the Madrigal numbers.

Let's not forget that the low dose (75mg) of CRV431 did in just 28 days what Madrigal's drug took 12 weeks to accomplish.
What's the 225mg dose of CRV431 gonna do, and what about over more time than that ultra-brief 28 day period? Blow Madrigal completely out of the water, or what?




Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash burning under 5 million a quarter

$HEPA